baber/WOPTO huggingface dataset:
Patent NZ-546017-A (NZ)
Title: Fully human antibodies against human 4-1BB (cd137)
Inventor: JURE-KUNKEL MARIA
IPC: C07K16/28
Filed: 2004-10-12
Abstract: Disclosed is a monoclonal antibody or antigen-binding portion thereof tat specifically binds to 4-1BB, comprising a light chain variable region and a heavy chain variable region, wherein: said light chain variable region comprises a CDR1 having amino acids 44-54 of SEQ ID NO: 6, a CDR2 having amino acids 70-76 of SEQ ID NO: 6, and a CDR3 having amino acids 109-119 of SEQ ID NO: 6; and said heavy chain variable region comprises a CDR1 having amino acids 50-54 of SEQ ID NO: 3, a CDR2 having amino acids 69-84 of SEQ ID NO: 3, and a CDR3 having amino acids 117-129 of SEQ ID NO: 3.
Patent NZ-549257-A (NZ)
Title: Modulators of cannabinoid receptors
Inventor: OKUYAMA MASAHIRO
IPC: C07C69/76
Filed: 2005-02-21
Abstract: Disclosed is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein Z is NR1R2; A is phenyl; B is (CH2)n; Y is a polar functional group as disclosed in the specification and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of the compound of formula 1 in the preparation of a medicament for treating a muscular disorder or a gastrointestinal disorder.
Patent NZ-549387-A (NZ)
Title: Silicon chip token made of two half shells with electronic insert
Inventor: CHAPET PIERRE
IPC: A44C21/00
Filed: 2006-06-30
Abstract: Disclosed is a disc-shaped token having a body produced by multiple injections of plastic material. The token comprises of a disc-shaped single-piece core (14) of the body produced by a first injection of plastic material and a covering layer produced by a second injection of plastic material. The core has a central portion (24) defining the central portion of the body of the token and an annular peripheral portion (31) defining at least part of an edge of the body of the token. The second injection is around the peripheral portion of the core to produce in conjunction with the core one of, all, or almost all of the edge and of the annular peripheral portion of the body of the token. The core of the token incorporates an insert (28) embedded in the plastic material of the central portion of the body during the first injection and a contactless electronic microchip identification device (27). The insert is secured between a first half-shell (41) and a second half-shell (43) of a first injection mold during the first injection of plastic material. This results in the insert being embedded within the plastic material of the central portion of the resulting disc-shaped single-piece core as a single-piece construction with the body of the core upon completion of the first injection
Patent NZ-550558-A (NZ)
Title: Method and apparatus for controlled triggering of oxygen scavenging compositions utilizing a wrap-around shade
Inventor: GROSSMAN GREG
Filed: 2006-10-16
Abstract: An apparatus is provided for activating an oxygen scavenging composition that includes a plurality of UV lamps arranged in a bank and disposed in a UV chamber. The UV lamps include first and second sides through which UV light is transmittable. A series of guide rolls disposed in the UV chamber define a film pathway for directing a film in close proximity with the first and second sides of the UV lamps. The UV shade is arranged to wrap about the first and second sides of the UV lamps, and may be configured to move between an open, partially open, and closed position so that the dosage of UV light to which the film is exposed may be controlled by adjusting the degree to which the shade is open. As a result, the UV shade may limit UV exposure without having to turn off the UV lamps.
Patent NZ-553502-A (NZ)
Title: Web-based automated code delivery
Inventor: SIMON MICHAEL P
Filed: 2005-08-30
Abstract: A method for obtaining a code and preventing disablement of a device is disclosed. The method includes the steps of: assigning a contract identification code associated with a loan contract, a payment centre receiving a loan payment, forwarding the payment from the payment centre to a finance company, where the finance company has an interest in the device, a code delivery computer determining whether the finance company has received the payment, the code delivery computer determining a previous code released for the device, releasing a new code subsequent to the previous code released for the device if the code delivery computer determines that the finance company has received the payment, the code delivery computer receiving the associated contract identification code from a user via telephony, an internet link, or an email, the code delivery computer providing the new code directly to the user via telephony, an internet link, or an email, the device receiving the code from the user, thereby preventing disablement of the device. The method is used to enable or disable devices such as car wheel clamps which may be used as incentives to encourage people to pay moneys owed.
Patent NZ-563392-A (NZ)
Title: Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
Inventor: SILENCE KAREN
IPC: A61K38/36
Filed: 2006-05-19
Abstract: A protein or polypeptide, which comprises two identical Nanobodies, wherein said nanobody is directed against Von Willebrand Factor (vWF), and said nanobody consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which: i) CDR1 essentially consists of: - the amino acid sequence YNPMG [SEQ 10 NO: 22]; or - an amino acid sequence that has 2 or 1 amino acid difference(s) with the amino acid sequence YNPMG [SEQ 10 NO: 22]; and in which: ii) CDR2 essentially consists of an amino acid sequence chosen from the group consisting of: - the amino acid sequence AISRTGGSTYYPDSVEG [SEQ 10 NO: 32]; - an amino acid sequence that has at least 80% sequence identity with the amino acid sequence AISRTGGSTYVPDSVEG [SEQ 10 NO: 32]; and - an amino acid sequence that has 2 or 1 amino acid difference(s) with the amino acid sequence AISRTGGSTYVPDSVEG [SEQ 10 NO: 32]; and in which: iii) CDR3 essentially consists of an amino acid sequence chosen from the group consisting of: - the amino acid sequence AGVRAEDGRVRTLPSEYTF [SEQ 10 NO: 42]; - an amino acid sequence that has at least 80% sequence identity with the amino acid sequence AGVRAEDGRVRTLPSEYTF [SEQ 10 NO: 42]; and - an amino acid sequence that has 1 amino acid difference with the amino acid sequence AGVRAEDGRVRTLPSEYTF [SEQ 10 NO: 42]. Also disclosed are pharmaceutical compositions comprising the above polypeptides and the use of the polypeptide in the treatment of disorders related to platelet-mediated aggregation.
Patent NZ-566580-A (NZ)
Title: Use of C3-C10 17alpha-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
Inventor: MORO LUIGI
IPC: A61K31/567
Filed: 2006-06-08
Abstract: Disclosed is the use of a C3-C10 17alpha-ester of 9,11-dehydrocortexolone having the formula (I) in which R1 is hydrogen and R2 is a C4 acyl, for the preparation of an antigonadotrophic medicine for: the treatment of prostate tumour, polycystic ovary, hot flushes in women or gonadotrophin-dependent precocious puberty; control of aberrant sexual behaviour; male contraception; and/or in ovarian stimulation in assisted fertilization methods, in which said medicine is formulated for systemic administration. Also disclosed is a composition comprising said ester and a method of male contraception comprising said ester.
Patent NZ-568825-A (NZ)
Title: Vaccine adjuvant comprising saponin and lipopolysaccharide
Inventor: VANDEPAPELIERE PIERRE
IPC: A61K39/145
Filed: 2006-12-12
Abstract: Disclosed is an adjuvanted vaccine compositions where the adjuvant is a liposomal formulation, comprising a saponin and a lipopolysaccharide. Disclosed is an immunogenic composition in a volume suitable for a human dose comprising an antigen, in combination with an adjuvant which adjuvant comprises QS21 presented in the form of a liposome and 3D-MPL wherein said QS21 and said 3D-MPL are both present in said human dose at a level of between 20 micrograms and 30 micrograms. The antigen in the immunogenic composition can be derived from M. tuberculosis, varicella zoster virus (VZV), human cytomegalovirus (HCMV), HIV-1, or Chlamydia spp.
Patent NZ-580327-A (NZ)
Title: IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
Inventor: RIZZI JAMES P
IPC: A61P35/00
Filed: 2008-03-27
Abstract: Discloses imidazo[I,2-a]pyridine compounds, or a pharmaceutically acceptable salt thereof, bearing a quinolinyl group at the 3 position of the imidazopyridine ring with the general structure as shown in the figure. Further disclosed are methods for preparation of claimed compounds. Imidazo[I,2-a]pyridine compounds are inhibitors of receptor tyrosine kinases, and the therapeutic application is in the treatment of diseases mediated by class 3 and 5 receptor tyrosine kinases i.e. cancers and autoimmune disorders.
Patent NZ-583064-A (NZ)
Title: New process for the synthesis of (7-methoxy-1-naphthyl)acetonitrile and application in the synthesis of agomelatine
Inventor: HERMET JEAN-PAUL
IPC: C07C253/14
Filed: 2008-08-01
Abstract: Disclosed herein is a process for the industrial synthesis of the compound of 7-methoxy-1-naphthyl)acetonitrile (compound of formula I), characterised in that 7-methoxy1-1naphthoic acid of formula (III) is used for the reaction which is further subjected to the action of a reducing agent to yield the compound 7-methoxy-1-naphthyl)methanol (formula (IV)), wherein the OH function of the compound of formula (IV) is converted into a leaving group and which is reacted with a cyanation reagent to yield the compound of formula (I), which is isolated in the form of a solid. Also disclosed is a process for the synthesis of agomelatine (compound of formula (II))starting from the compound of formula (I), characterised in that the compound of formula(I) is obtained by the synthesis process described above and is subjected to reduction and then to coupling with acetic anhydride.
Patent NZ-592497-A (NZ)
Title: Derivatives of 1-amino-2-cyclobutylethylboronic acid
Inventor: FLEMING PAUL E
IPC: A61K35/00
Filed: 2009-09-25
Abstract: 585460 Disclosed is a compound of formula (I).
Patent NZ-595371-A (NZ)
Title: A method and a mixing station for mixing of bulk solid materials with broad particle size distribution
Inventor: KARLSEN MORTEN
IPC: B01F23/00
Filed: 2010-03-26
Abstract: 595371 A mixing station for mixing at least two bulk solid materials, wherein at least one of these materials has variations in particle size distribution, comprises a first gravimetric mixer and a second mixer. The first gravimetric mixer is formed as a silo (9) with an upper part having plural chambers (see 4 & 4’, figure 3b) for homogenisation of at least one of the materials, and includes a converging lower hopper (2”) with an outlet (3). In use, the material having variations in particle size distribution is fed sequentially into the plural chambers of the first gravimetric mixer, where all chambers are then discharged simultaneously via the hopper to mix the particles in a combined mass flow. The second mixer is provided for mixing the homogenised material from the first gravimetric mixer with the other of the at least two bulk solid materials. A method for mixing at least two bulk solid materials is also provided.
Patent NZ-601396-A (NZ)
Title: Robotized transport and transfer system
Inventor: GIASSON ETIENNE
IPC: B25J9/00
Filed: 2010-12-06
Abstract: 601396 Disclosed is a system and method for transferring and transporting a flexible package (102). The system comprises of a multi-axis robot (101) for transferring and displacing the flexible package (102) between a first and second position. A lift assist platform (104) comprises a displacing system and transports the flexible package (102) and supports the weight of the package between first and second positions. The method involves providing a system comprising of a multi-axis robot (101); a lift assist platform (104), a semi-automatic bagger (9) and a closing system (7). The flexible package (102) is filled with a substance and the top sidewalls of the package are brought together using a package closing configuration. The lift assist platform (104) lifts to support the weight of the package (102). The multi-axis robot (101) grasps the top of the package (102) and maintains its shape. The package (102) is released from the semi-automatic bagger (9). Through synchronised motion of the multi-axis robot (101) and the lift assist platform (104), the flexible package (102) is displaced towards an inlet of the closing system (7). The flexible package (102) is aligned and transferred from the multi-axis robot (101) to the closing system (7).
Patent NZ-603377-A (NZ)
Title: Beater tool for a stand mixer comprising a scraper
Inventor: SEIDLER MARK
IPC: A47J43/07
Filed: 2011-05-06
Abstract: 603377 Beater assembly for mixing ingredients in the bowl of a stand mixer with planetary drive is disclosed. The assembly (10) includes upright arm members (12, 14) which repeatedly approach and pass close to the walls of the bowl in accordance with the motion imparted by the planetary drive. The arm members are provided with flexible wiping or scraping blades (22) which are capable of adapting themselves to fully conform to the bowl surface, each arm member (12, 14) is grooved (24) along its length and each blade (22) is formed of a length-wise resilient elastomer configured for mounting in the groove. The blades are formed at each end with fasteners (34, 36) and are held in position, under length-wise tension, by interlocking the fasteners with anchoring devices (38, 40) located near the ends of the arm members.
Patent NZ-613335-A (NZ)
Title: Agent for inducing interferon production containing lactic acid bacteria
Inventor: FUJIWARA DAISUKE
IPC: A61K35/747
Filed: 2011-12-28
Abstract: Disclosed is a use of Lactococcus lactis JCM5805 or Lactococcus lactis JCM20101, capable of activating plasmacytoid dendritic cells (pDCs) and inducing IFN production, or a cultured or processed product thereof in the manufacture of an agent for inducing IFN production.
Patent NZ-627015-A (NZ)
Title: Height safety anchor
Inventor: ARVO POLDMAA
IPC: E04G21/32
Filed: 2014-07-02
Abstract: Disclosed is a height safety anchor (11a) for fitment to a building support structure to provide fall protection through reduced shock forces or impact to a user that was located on a roof or high structure without safety barriers. The height safety anchor comprises a first attachment means 15a for fitment to the building support structure; a second attachment means 16a remote from the first attachment means for attaching safety equipment; and shock absorbing means 13a having a serpentine plastic deforming shock absorbing member having a deformable region 19 extending between the first and second attachment means in a first length when not subject to a deformation force corresponding to a critical sudden load, the shock absorbing means lying substantially in a single plane and comprising a substantially rigid structure that, when subject to the critical sudden load, deforms, elongating to a greater length than the first length. The first attachment is attached to the building support structure by engagement to a flexible and high tensile elongate member (12) such as a steel wire cable of rope comprising a plurality of spaced eyelets (18a) that are slidable along the elongate member.
Patent NZ-630063-A (NZ)
Title: Improvements relating to tactile ground surface indicators
Inventor: DEDOMENICO DANIEL
IPC: G09F19/22
Filed: 2013-02-13
Abstract: Methods for manufacturing truncated dome inserts or studs for tactile paving for the blind are described. The insert (100’) is formed by combining a frustoconical head or flange (5) with a stem or shaft (30) and applying a coating (16).
Patent NZ-714931-A (NZ)
Title: Nuclear transport modulators and uses thereof
Inventor: SHECHTER SHARON
IPC: C07D249/08
Filed: 2014-06-20
Abstract: The present invention relates to compounds of formula IV: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula IV or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
Patent NZ-737412-A (NZ)
Title: 5-ht2c receptor agonists and compositions and methods of use
Inventor: REN ALBERT S
IPC: A61P25/00
Filed: 2016-04-26
Abstract: Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent.
Patent NZ-743378-A (NZ)
Title: Methods and systems for generating workflows for analysing large data sets
Inventor: SINGH DADABHAI T
IPC: G06Q10/06
Filed: 2015-11-12
Abstract: A method is proposed for designing a computational process for performing a computational task such as a next generation sequencing task. A user who wishes to instigate the workflow for analysing a dataset is presented with a graphical user interface (GUI) comprising plurality of areas representative of respective associated data analysis algorithms, each of the algorithms being characterized by one or more numerical parameters. Default values have been defined for some or all of the numerical parameters, and one of more of the parameters of each algorithm may be modified using the GUI. The GUI allows the user to select and combine a plurality of the icons (e.g. by drag and drop operations) and set one or more of the modifiable parameters, to form a workflow comprising the corresponding algorithms.
Patent NZ-750005-A (NZ)
Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
Inventor: RABINOVICH BRIAN
IPC: C07K16/28
Filed: 2017-07-07
Abstract: The present disclosure provides proteins, such as antibodies, that include an antigen binding portion that specifically binds to Programmed Death 1 Ligand 1 (PD-L1). Also provided are nucleic acids encoding the proteins, and cells (e.g., genetically modified cytotoxic lymphocytes) that include such nucleic acids. In some embodiments, a subject method includes reducing the interaction between PD-L1 on a first-cell and PD-1 on a second cell. In some cases, the contacting is in vivo. For example, the methods and compositions provided can be used in the treatment of viral infection and cancer, such as the treatment of solid tumors via ACT or via administration of a subject protein that specifically binds to PD-L1.
Patent NZ-753171-A (NZ)
Title: 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof
Inventor: YOO SANG KU
IPC: C07D311/02
Filed: 2017-09-27
Abstract: The present invention relates to a method for synthesizing a 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and an optical isomer thereof, and an intermediate Compound (Chemical Formula 3 or 4) which may be used for the synthesis method, and when the method and the intermediate Compound are used, the 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and the optical isomer thereof may be effectively synthesized.
Patent NZ-759992-A (NZ)
Title: Tuning and calibration features of a sequence-detection system
Inventor: MANDELL JEFFREY G
IPC: C12Q1/68
Filed: 2018-09-14
Abstract: The current document discusses electromechanical sequence detectors that transduce changes in the shape of a shape-change sensor component into an electrical signal from which one or more derived values are generated. In a disclosed implementation, the sequence-detection system comprises a mechanical-change sensor that changes shape when specifically interacting with entities within a target, a shape-to-signal-transduction component that transduces changes in the shape of the mechanical-change sensor into an electrical signal, an analysis subsystem that determines the types of entities within the target using the electrical signal, and a control subsystem that continuously monitors operational characteristics of the sequence-detection system and adjusts sequence-detection system operational parameters.
Patent PT-102299-A (PT)
Title: Hydrometallurgical beneficiation of multi metal pyrite ores - comprises extraction from sulphides by oxidation cementation in aqueous solution, solvent extraction and lixiviation
Inventor: NOGUEIRA EDUARDO DIAZ
IPC: C22B15/00
Filed: 1999-05-06
Abstract: The hydrometallurgical beneficiation of multi-metal pyrite ores comprises treatment of ores containing smallish amounts of sulphides of copper, zinc, lead and silver. The copper, zinc, lead and silver are extracted by oxidation in aqueous medium with oxygen at high pressure and temperature, combined with selective-solvent-based extraction of copper and zinc, and cementation of the lead and the silver solubilised in the lixiviation of the ferric residue with brine and membrane-based separation.
Patent PT-107754-A (PT)
Title: Sistema de localização com gestão energética inteligente
Inventor: FALCÃO MÁRIO JOÃO NAZARETH
IPC: D04B1/24
Filed: 2014-07-07
Abstract: O PRESENTE MODELO REFERE-SE A UM MÉTODO DE GESTÃO ENERGÉTICA DE ELEVADA EFICIÊNCIA APLICADO A UM SISTEMA DE LOCALIZAÇÃO GEOGRÁFICA COMPOSTO POR UM DISPOSITIVO ELETRÓNICO E UM SISTEMA APLICACIONAL PROPRIETÁRIO QUE INTERAGEM ENTRE SI ATRAVÉS DE UMA REDE MÓVEL CELULAR. ATRAVÉS DA REDE MÓVEL O DISPOSITIVO ELETRÓNICO QUE DISPÕE DE ENERGIA PRÓPRIA ESTABELECE COMUNICAÇÃO COM O SISTEMA APLICACIONAL, VIA MEIOS TECNOLÓGICOS CONVENCIONAIS, DESIGNADAMENTE PÁGINAS INTERNET, MENSAGENS DE TELEMÓVEL OU CORREIO ELETRÓNICO, PERMITINDO AO UTILIZADOR A MONITORIZAÇÃO REMOTA DO DISPOSITIVO. DIRECIONADO PARA SUPORTE À SEGURANÇA DE PESSOAS, ANIMAIS E BENS EM QUE A PORTABILIDADE CONSTITUI FATOR CRÍTICO DE SUCESSO, DA APLICAÇÃO DE TAL MÉTODO RESULTOU UMA REDUÇÃO SIGNIFICATIVA DA DIMENSÃO FÍSICA DO EQUIPAMENTO E UM AUMENTO EXPRESSIVO DA SUA AUTONOMIA, FACE AO EXISTENTE NO MERCADO PARA ESTE FIM. APLICÁVEL EM QUALQUER LUGAR ONDE EXISTA A REFERIDA INFRAESTRUTURA DE COMUNICAÇÃO, NÃO POSSUI BARREIRAS GEOGRÁFICAS, COMO TAL DE APLICAÇÃO A UMA ESCALA INTERNACIONAL.